Metropolitan Hospital — Clinical Trial Site

80 Registered trials

39 Currently recruiting

Organisation

Metropolitan Hospital

Location

Pireas, Greece

Identifier

ORG-100022582

Address

Ethnarchi Makariou 9, 185 47, Greece

Departments

#2400:Cardiology Department
#2504: Preventive Cardiology Department
#3003: 4th Oncology Department
03004: 4th Oncology clinic
1st Department of Oncology
1st Dept of Oncology
1st Oncology Clinic
1st Oncology Clinic
1st Oncology Department
2nd Cardiology Dpt
2nd Department of Medical Oncology,
2nd Oncology Clinic
2nd Oncology Department
2nd Oncology Department, 2nd Building
3008: 4th Oncology Department
4rth Oncology Clinic
4th Department of Oncology
4th Oncology clinic
4th Oncology Department
4th Oncology Dept
A Oncology Clinic
A Oncology Department
A' Oncology Clinic
A’ Oncology Clinic
B'Oncology
D' Oncology Clinic
D’ Oncology Department
Department of Neurology
Fourth Oncology Department & Comprehensive Clinical Trials Center
Preventive Cardiology Department
Preventive Cardiology, Lipid Clinic and LDL Apheresis
Stroke Unit
Β΄ Oncology Department

Clinical trials at this site (80)

Search interface

Study of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer… Recruiting

2024-516982-35-00 Ovarian Cancer 5 2025-09-11
A clinical study of V940 and pembrolizumab in people with melanoma (V940-012) Recruiting

2024-519605-36-00 Melanoma 4 2025-08-08
Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer Recruiting

2024-515884-69-00 Extensive Stage Small Cell Lung Cancer (ES-SCLC) 5 2025-07-16
A Study to Assess the Adverse Events and Change in Disease Activity of Multiple Treatment Combinations with Telisotuzumab Adizutecan in Part… Recruiting

2024-512981-33-00 Metastatic Colorectal Cancer 4 2025-07-09
A clinical study of V940 and pembrolizumab to treat lung cancer (V940-009) Recruiting

2023-506327-29-00 Non-Small Cell Lung Cancer 5 2025-05-14
KEYMAKER U01 Sub-Study E Signal-finding study to test investigational agents with pembrolizumab in combination with chemotherapy in newly di… Recruiting

2023-509234-19-00 Participants With Newly Diagnosed Resectable Stages II- 4 2025-03-03
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca… Recruiting

2022-502352-31-00 Colorectal Cancer (CRC) 5 2025-02-10
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Can… Recruiting

2023-509340-10-00 Patients with HLA-A2 positive phenotype and metastatic 5 2024-10-29
IMPlementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older bReasT cAncer patieNTs – a pragmatic randomized-contr… Recruiting

2023-506620-87-00 Advanced Breast Cancer in older patients 11 2024-01-25
A Study Evaluating the Overall Survival of Patients with Extensive Stage Small Cell Lung Cancer Receiving Trilaciclib or Placebo prior to To… Recruiting

2022-502357-34-00 Extensive Stage Small Cell Lung Cancer 5 2023-09-27
This study has 2 phases: a Phase 1b evaluation of elacestrant in combination with abemaciclib followed by a Phase 2 evaluation of elacestran… Recruiting

2024-512878-98-00 Brain Metastasis from Estrogen Receptor Positive, HER-2 9 2023-05-16
Long-term safety and tolerability of inclisiran in participants with heterozygous familial hypercholesterolaemia or homozygous familial hype… Recruiting

2023-507278-41-00 Familial hypercholsterolemia 5 2023-02-10
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectabl… Recruiting

2023-506891-28-00 The target population of interest in this study is part 5 2022-05-02
Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma… Recruiting

2023-508922-83-00 Advanced Non-Small Cell Lung Cancer 10 2021-03-17
Pan tumor Roll Over Study Recruiting

2023-506914-32-00 Pan tumor 4 2020-05-05
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with SCLC Ended

2024-516051-40-00 Small Cell Lung Cancer (SCLC) 4 2025-06-10
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Progressive Metastatic Castration-… Ended

2024-513968-25-00 Metastatic castration-resistant prostate cancer (mCRPC) 5 2025-04-28
Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended

2024-513621-23-00 Advanced/metastatic non-small cell lung cancer (NSCLC) 5 2025-04-18
A study to learn if a combination of Fianlimab and Cemiplimab versus Cemiplimab alone is more effective for adult participants with Advanced… Ended

2022-501483-18-00 Advanced Non-Small Cell Lung Cancer 10 2025-03-28
Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLph… Ended

2023-505989-29-00 Extensive stage small cell lung cancer (ES-SCLC) 5 2024-11-21
A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation Ended

2023-503714-77-00 Advanced Non-Small Cell Lung Cancer 4 2024-10-01
A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended

2023-504753-12-00 Lung Cancer, Non-Small Cell 5 2024-10-01
Effects of the combination of two drugs called irbesartan and amlodipine, in one pill in patients with high blood pressure. Ended

2024-511705-31-00 Arterial Hypertension 5 2024-09-26
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with previously treated KRAS G12C-positive… Ended

2024-510908-37-00 KRAS G12C-Positive Advanced or Metastatic Non-Small Cel 5 2024-08-28